Last reviewed 2026-05-14 · How we verify

Aricept (donepezil SR 23 mg)

Donepezil is an acetylcholinesterase inhibitor that increases acetylcholine levels in the brain by blocking the enzyme that breaks it down.

Donepezil is an acetylcholinesterase inhibitor that increases acetylcholine levels in the brain by blocking the enzyme that breaks it down. Used for Mild to moderate Alzheimer's disease, Moderate to severe Alzheimer's disease.

At a glance

Mechanism of action

By inhibiting acetylcholinesterase, donepezil prevents the degradation of acetylcholine, leading to increased cholinergic neurotransmission in the central nervous system. This enhancement of acetylcholine signaling helps improve cognitive function and memory in patients with Alzheimer's disease. The sustained-release (SR) 23 mg formulation provides extended drug delivery over 24 hours.

Approved indications

• Mild to moderate Alzheimer's disease
• Moderate to severe Alzheimer's disease

Common side effects

• Nausea
• Diarrhea
• Vomiting
• Muscle cramps
• Fatigue
• Insomnia
• Syncope

Key clinical trials

• Open-Label Extension Study of 23 mg Donepezil SR in Participants With Moderate to Severe Alzheimer's Disease (PHASE3)
• A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia (PHASE2)
• Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Aricept (donepezil SR 23 mg) CI brief — competitive landscape report
• Aricept (donepezil SR 23 mg) updates RSS · CI watch RSS
• Eisai Inc. portfolio CI